Flibanserin
After previous denial, in 2015, the American Food and Drug Administration (FDA) approved flibanserin (brand name Addyi) for the treatment of low sexual desire in premenopausal women. Flibanserin has mixed effects on the serotonergic and dopaminergic neurotransmitter systems and was...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.